Literature DB >> 155075

Mechanism of the hypocalcemic effect of mithramycin.

D T Kiang, M K Loken, B J Kennedy.   

Abstract

Mithramycin is effective in the treatment of hypercalcemia. The mechanism of its hypocalcemic effect was studied in six patients with hypercalcemia by serum 85Sr or 45Ca kinetic techniques. Mithramycin was given at two dosage levels (25 or 50 microgram/kg iv). Mithramycin at the low dosage had little effect on the rate of bone accretion. However, at both dosage levels, mithramycin caused an upward shift of the slope of the specific activity curve, indicating an inhibitory effect on bone resorption. This effect started 6-12 h after a 25-microgram/kg dose of mithramycin and lasted from 4-6 days. It appears that mithramycin has a preferential effect on bone resorption.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 155075     DOI: 10.1210/jcem-48-2-341

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Molecular insight into substrate recognition and catalysis of Baeyer-Villiger monooxygenase MtmOIV, the key frame-modifying enzyme in the biosynthesis of anticancer agent mithramycin.

Authors:  Mary A Bosserman; Theresa Downey; Nicholas Noinaj; Susan K Buchanan; Jürgen Rohr
Journal:  ACS Chem Biol       Date:  2013-09-13       Impact factor: 5.100

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Treatment of hypercalcaemia associated with malignancy.

Authors:  R Wilkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-17

Review 4.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 5.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

6.  Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.

Authors:  M F Attie; M D Fallon; B Spar; J S Wolf; E Slatopolsky; S Goldfarb
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

7.  Hypercalcaemia in cerebellar medulloblastoma: pathogenesis of solid tumour-associated hypercalcaemia.

Authors:  O Arisaka; K Obinata; K Yabuta; K Ishimoto; K Sato
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

8.  Influence of urinary sodium excretion on the clinical assessment of renal tubular calcium reabsorption in hypercalcaemic man.

Authors:  S H Ralston; M D Gardner; F J Dryburgh; R A Cowan; I T Boyle
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

9.  Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis.

Authors:  P J Heyburn; J A Child; M Peacock
Journal:  J Clin Pathol       Date:  1981-01       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.